Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Foerster

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cell Death & Disease|August 29, 2014
Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛF Foerster, S Braig, C Moser, et al.
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cell Death & Disease|August 29, 2014
Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛF Foerster, S Braig, C Moser, et al.
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Pageof 4